量化淋巴结负荷作为「极高危」因素识别从术后放化疗获益的头颈癌患者
该研究基于美国国家癌症数据库2004至2014年接受手术、颈清扫及术后放疗的非口咽头颈鳞癌患者共7144例,采用多因素回归及交互项分析发现,阳性淋巴结数量越多,术后放化疗较单纯放疗的生存获益越大;0-2枚阳性淋巴结者无获益,3-5枚及≥6枚者获益递增,且无论切缘状态或结外扩展如何,仅≥6枚阳性淋巴结者从术后放化疗中生存改善。
要点
- 非口咽头颈鳞癌术后阳性淋巴结数量是预测放化疗获益的关键因素。
- 0-2枚阳性淋巴结者术后放化疗无生存获益(HR 0.96)。
- ≥6枚阳性淋巴结者从术后放化疗中获益最大(HR 0.65)。
核心结论
- 转移性淋巴结负荷增加与术后放化疗较单纯放疗的获益增加相关,在识别放化疗获益人群方面优于传统高危因素。
- 按转移性淋巴结数量分层可能界定出最适合治疗强化的极高危患者队列。
研究设计与样本
- 基于美国国家癌症数据库的回顾性队列分析,纳入2004至2014年诊断为非口咽头颈鳞癌(口腔、喉、下咽)并接受手术切除、颈清扫及术后放疗的患者7144例。
- 采用多因素回归及一阶交互项分析术后放化疗与连续阳性淋巴结数量对总生存的交互作用。
主要发现
- 多因素分析中,阳性淋巴结数量增加与死亡率增加相关(P < 0.001)。
- 阳性淋巴结数量增加与术后放化疗较单纯放疗的获益增加相关(交互P < 0.001)。
- 0-2枚阳性淋巴结患者术后放化疗无获益(HR 0.96,95%CI 0.86-1.07,P = 0.47)。
- 3-5枚阳性淋巴结患者术后放化疗获益增加(HR 0.84,95%CI 0.70-1.00,P = 0.05)。
- ≥6枚阳性淋巴结患者术后放化疗获益增加(HR 0.65,95%CI 0.51-0.82,P < 0.001)。
关键数值与推荐
- 术后放化疗与阳性淋巴结数量的交互作用P < 0.001。
- 0-2枚阳性淋巴结:HR 0.96,95%CI 0.86-1.07,P = 0.47。
- 3-5枚阳性淋巴结:HR 0.84,95%CI 0.70-1.00,P = 0.05。
- ≥6枚阳性淋巴结:HR 0.65,95%CI 0.51-0.82,P < 0.001。
临床怎么用
- 原文结论提出按转移性淋巴结数量分层可能界定出最适合治疗强化的极高危患者队列,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adjuvant chemoradiation (CRT) is standard for head and neck squamous cell carcinoma (HNSCC) patients with positive margins or extranodal extension (ENE) following surgery. However, emerging evidence suggests the number of positive lymph nodes (LNs) is the dominant determinant of survival in non-oropharyngeal HNSCC and thus may better identify those benefiting from treatment intensification. PATIENTS AND METHODS: Patients from the National Cancer Database diagnosed with non-oropharyngeal HNSCC (oral cavity, larynx, hypopharynx) between 2004 and 2014 and undergoing surgical resection, neck dissection, and postoperative radiotherapy (RT) were included. Multivariable regression with first-order interaction terms was used to model the interaction between postoperative CRT and continuous number of positive LNs with respect to overall survival. RESULTS: In total, 7144 patients met inclusion criteria. In multivariable analysis, increasing number of positive LNs was associated with both increasing mortality (P < 0.001) and increasing benefit from postoperative CRT versus RT alone (interaction P < 0.001). While there was no benefit from postoperative CRT in patients with 0-2 LN+ [hazard ratio (HR) 0.96, 95% confidence interval (CI) 0.86-1.07, P = 0.47], increased benefit was seen in those with 3-5 LN+ (HR 0.84, 95% CI 0.70-1.00, P = 0.05) and those with ≥6 LN+ (HR 0.65, 95% CI 0.51-0.82, P < 0.001) in multivariable models. By contrast, margin status and ENE did not reliably identify patients benefitting from postoperative CRT based on statistical tests of interaction. Even in patients with ENE, positive margins, or both, only those with ≥6 LN+ had improved survival with postoperative CRT. CONCLUSION: Increasing metastatic nodal burden was associated with increased benefit from CRT compared with RT alone, surpassing conventional high-risk factors in identifying patients benefiting from CRT. Stratification by metastatic LN number may characterize a very-high-risk patient cohort best suited for treatment intensification.
引用
- Zumsteg ZS, Luu M, Kim S, et al. Quantitative lymph node burden as a 'very-high-risk' factor identifying head and neck cancer patients benefiting from postoperative chemoradiation. Ann Oncol. 2019. PMID: 30395159. doi:10.1093/annonc/mdy490
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。